Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical Phase Ib trial of the company’s candidate drug MIV-711 has commenced. MIV-711 is a cathepsin K inhibitor intended to treat skeletal disorders that feature high bone resorption such as osteoporosis, rheumatoid arthritis and bone metastases.
The Sacramento Bee